ArticleJournal of ginseng research2025
Ginsenoside Rb1 attenuates age-associated cognitive impairment by modulating oxidative stress and the SIRT1/eNOS/NO axis.
Article in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Ginsenosides Rh2 and Rg3 in first-line combination therapy: Prospects for rapid clinical translation in drug-resistant triple-negative breast cancer.Journal of ginseng research · 2026Review
- Ginsenoside Re Attenuates D-Galactose-Induced Aging-like Oxidative Stress in Cultured Bovine Oocytes via Activation of the SIRT1/Nrf2 Signaling Pathway.International journal of molecular sciences · 2026Article
- Ginsenosides fromJournal of ginseng research · 2026Review
- Review
- SIRT1: The first key to unlocking the mystery of cardiovascular diseases.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In traditional Chinese medicine ginseng, ginsenoside Rb1 (Rb1) is an active compound that has been shown to alleviate oxidative stress, modulate autophagy, and inhibit apoptosis. However, its role in the natural aging process remains unknown. Aim: Investigate the role of Rb1 in natural aging and potential molecular mechanisms. Methods: During eight weeks of treatment with Rb1, we administered low-dose (10 mg/kg·d) or high-dose (20 mg/kg·d) Rb1 to middle-aged (12-month-old) and aged (20-month-old) mice, and observed how changes in body weight and spatial learning were related to aging symptoms. Further, we measured oxidative stress-related markers and nitric oxide (NO) levels in the mice's hippocampal tissue after Rb1 treatment, and identified aging-related biomarkers and pathways. Results: Treatment with Rb1 greatly reduced the physiological changes associated with aging, such as the weight loss slowing, the inhibition of the loss of visuospatial learning and memory ability, and the senescence of brain tissues. Mice treated with Rb1 had lower serum levels of malondialdehyde (MDA) and higher superoxide dismutase (SOD) activity, along with a reduction in the release of pro-inflammatory markers such tumor necrosis factor-α (TNF-α) and Interleukin-6 (IL-6). Furthermore, Rb1 therapy raised serum NO levels and improved Sirtuin 1 (SIRT1) protein expression, indicating that its anti-aging benefits are connected to the control of the SIRT1/eNOS/NO axis. Conclusions: Rb1 modulates the SIRT1/eNOS/NO axis, which is linked to reducing oxidative stress and inflammatory reactions, hence delaying the aging process in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.